Jon Ehrmann
Overview
Explore the profile of Jon Ehrmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
3
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ehrmann J, Generaux C, Ostergaard S, Johnson W, Rose A, Mendenhall V
J Invest Surg
. 2021 Feb;
35(3):502-510.
PMID: 33622163
Biologic therapeutics constitute up to 30% of all drugs approved from 2010 to 2018 and represent a continuous growing market. In contrast to small molecules, biologic therapeutics (>1 kDa MW)...
2.
Graham M, Stoll L, Ehrmann J
J Invest Surg
. 2019 Aug;
32(8):773-784.
PMID: 31455106
The 34th Annual Meeting of the Academy of Surgical Research was held from September 26-28, 2018 in Charleston, South Carolina. The Academy's community joins together at the annual meeting to...
3.
Graham M, Ziegelhofer T, Ehrmann J
J Invest Surg
. 2018 Apr;
32(6):573-585.
PMID: 29641265
The 33rd Annual Meeting of the Academy of Surgical Research was held from October 4 to 6, 2017 in Las Vegas, Nevada. The meeting welcomed >160 participants from 27 different...
4.
Narang A, Balakrishnan A, Morrison J, Li J, Wang J, Gu H, et al.
Eur J Pharm Biopharm
. 2017 Apr;
117:333-345.
PMID: 28455207
Variability in oral absorption in pre-clinical species makes human dose projection challenging. In this study, we investigated the mechanistic basis of variability in oral absorption of a model hydrophobic compound...
5.
West W, Ehrmann J, Johnson W
J Invest Surg
. 2014 Apr;
27(4):226-33.
PMID: 24694254
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder characterized by an excessive production of extracellular amyloid plaques and intracellular neurofibrillary tangles in the brain. Studies have shown that concentrations of...
6.
Foster K, Morgen M, Murri B, Yates I, Fancher R, Ehrmann J, et al.
Int J Pharm
. 2012 Jun;
434(1-2):406-12.
PMID: 22692076
Target validation or demonstration of efficacy requires adequate in vivo exposure of tool molecules to determine their activity in order to validate the model or show the potential usefulness of...